Biogen (BIIB) Depreciation & Amortization (CF) (2009 - 2026)

Biogen's Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $204.4 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 11.57% year-over-year to $204.4 million; the TTM figure through Mar 2026 stood at $801.1 million (up 13.01% YoY), while the FY2025 annual figure was $779.9 million, up 15.85% from the prior year.
• Depreciation & Amortization (CF) was $204.4 million for Q1 2026 at Biogen, up from $200.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $204.4 million in Q1 2026 to a low of $112.3 million in Q1 2023.
• Historically, Depreciation & Amortization (CF) has averaged $157.1 million across 5 years, with a median of $147.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) fell 21.52% in 2023, then soared 46.24% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $119.8 million in 2022, then rose by 16.94% to $140.1 million in 2023, then soared by 31.33% to $184.0 million in 2024, then increased by 8.8% to $200.2 million in 2025, then rose by 2.1% to $204.4 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $204.4 million (Q1 2026), $200.2 million (Q4 2025), and $202.2 million (Q3 2025), per Business Quant data.